JNNP Podcast

1. Nitrous Oxide Abuse

With the UK government announcing plans to make recreational use of nitrous oxide illegal, JNNP podcast host Dr. Saima Chaudhry (1) is joined by London-based neurologist Dr. Alastair Noyce (2)(3) to examine the findings of his group's recently published research paper, "Nitrous oxide-induced myeloneuropathy: a case series". Read the paper here: https://jnnp.bmj.com/content/94/9/681Related links:https://www.gov.uk/government/news/nitrous-oxide-to-be-illegal-by-end-of-the-year(1) Warren Alpert Med

Sep 22,2023 27:45

2. Brain Fog Demystified

Social media platforms and clinical patient encounters are abundant in references to brain fog, but how much is it really understood? In this episode, JNNP's podcast host, Dr. Saima Chaudhry (1), speaks with Dr. Laura McWhirter (2) about her recently published article, "What is Brain Fog?"and how further understanding of this can help to better treat patients. You can read the paper at the following link: https://jnnp.bmj.com/content/94/4/321 (1) Warren Alpert Medical School, Brown University, R

Aug 08,2023 30:15

3. A roadmap to ALS prevention: strategies and priorities

In this episode, JNNP's new podcast host Dr. Saima Chaudhry (1) speaks with Dr. Michael Benatar (2) about his recently published article, "A roadmap to ALS prevention: strategies and priorities". This explores a new approach to Amyotrophic lateral sclerosis, with an emphasis on earlier treatment before significant damage has occurred. This is important due to the limited capacity of the central nervous system to repair itself. The researchers involved sought to understand contributing factors fo

Jun 15,2023 38:29

4. MOGAD: Definition, diagnosis and treatment

In this episode, JNNP's new podcast host Dr. Saima Chaudhry (1) speaks with Dr. Matteo Gastaldi (2) about Myelin oligodendrocyte glycoprotein antibody-associated disease, or MOGAD for short. A multi-centre retrospective study, "Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD", was recently published in JNNP, and Dr. Gastaldi is its first author. Listen to this podcast to learn what MOGAD is, its differential diagnosis and the potential pathogenes

May 15,2023 21:17

5. CGRP in migraine: current therapeutics, future implications and potential off-target effects

In this podcast, JNNP's Podcast Editor, Colin Mahoney, interviews Dr Jason Ray (Neurology, Alfred Health, and Department of Neuroscience, Monash University, Melbourne). Dr Ray discusses the role of calcitonin gene related peptide in migraine and the growing body of evidence for the role of therapies directed against this protein in migraine and beyond. He also highlights emerging off-target side effects to monitor for.Related article: https://jnnp.bmj.com/content/92/12/1325

Dec 21,2021 10:01

6. Alemtuzumab’s impact on functional and structural integrity of the visual system in MS

Prof Michael Barnett, Director Sydney Neuroimaging Analysis Centre and Professor of Neurology, University of Sydney, joins JNNP's Podcast Editor, Colin Mahoney, to discuss how the use of Alemtuzumab may have longer-term impacts on improving one of the most commonly involved neurological pathways, the visual system, in multiple sclerosis (MS). Prof Barnett discusses his team's results after following up patients with highly active MS for 24 months, using multifocal visual evoked potentials and ad

Nov 17,2021 20:02

7. Guidelines for the management of functional speech and communication disorders

A/Prof Jan Baker, Speech Pathologist, Flinders University and UTS. Dr Laura McWhirter, University of Edinburgh joins editor Colin Mahoney to discuss the first comprehensive guidelines developed to assist speech and language professionals in the management of functional communication, voice, swallow and cough disorders. As part of a global team they have developed a set of clinically focused guidelines in the recognition and management of theses disorders and discuss the highlights on the Podca

Sep 27,2021 23:09

8. The impact of traumatic brain injury on neurocognitive outcomes in children

Mark Goh and Shu-Ling Chong, Duke-NUS Medical School and KK Women's and Children's Hospital, Singapore joins editor Colin Mahoney to discuss their systematic review and meta-analysis spanning 6000 articles dealing with neurocognitive outcomes following traumatic brain injury (TBI) in children. They highlight how dose of TBI impacts executive function and memory with potentially long term impacts. https://jnnp.bmj.com/content/92/8/847

Aug 31,2021 09:54

9. Cerebral Microbleeds: from depiction to interpretation

Cerebral Microbleeds are increasingly recognised due to increased availability of neuroimaging and are known to be associated with increased risk of stroke, in particular intracerebral haemorrhage. In this podcast Dr Laurent Puy joins editor Colin Mahoney to discuss their histopathology, epidemiology and impact on clinical decision making in a state-of-the-art review published in June's JNNP.https://jnnp.bmj.com/content/92/6/598

Jul 05,2021 10:23

10. Motor functional neurological disease, a decade of progress

Over the last ten years, huge progress has been made in the common but often poorly understood condition of motor Functional Neurological Disorder (mFND). In this podcast, Dr W. Curt La France, Jr., Professor of Neurology and Psychiatry, Brown University, USA, joins editor Colin Mahoney to discuss diagnosis, insights on disease mechanisms, and emerging therapeutic approaches. They also highlight the stigma associated with mFND and ways to improve outcomes for patients.Read the paper on the JNNP

Jun 25,2021 09:52

11. COVID - 19 Vaccination and risk of large vessel arterial stroke

The Oxford Astra Zeneca vaccine has been associated with a rare complication of cerebral venous sinus thrombosis. Dr Colin Mahoney, JNNP Podcast Editor, interviews Prof David Werring, Professor of Clinical Neurology, UCL Queen Square Institute of Neurology, UK, about the new evidence which supports an association between vaccination and more common large vessel arterial stroke. They also discuss several cases, including treatment, and emerging biological evidence relating to causation. Read the

Jun 03,2021 13:15

12. Drug repurposing for progressive multiple sclerosis

Prof Alaisdair Coles and Dr Nick Cunniffe, The University of Cambridge joins editor Colin Mahoney to discuss:The work carried out by a team of researchers alongside the MS Society in the United Kingdom. The authors discuss the process of identifying therapies to repurpose in future MS trials and why they think this drugs may work. https://jnnp.bmj.com/content/92/3/295

Mar 02,2021 08:48

13. Isaacs syndrome the crossroads of Neurology, Psychiatry and Immunology

Rick Thurbon, patient editorial board member. Prof Matthew Kiernan and A/Prof Susanna Park from The University of Sydney joins editor Colin Mahoney to discuss:In 1960 a landmark paper was published by Hyam Isaac on a syndrome of continuous muscle activity. The spectrum of Isaac's Syndrome has broadly widened since then and we reflect on this with patients and experts in this field. https://jnnp.bmj.com/content/91/12/1243

Nov 25,2020 11:56

14. Apathy, cerebral small vessel disease and future dementia risk

Jonathan Tay joins our podcast editor Colin Mahoney to discuss the findings from two large cohort studies of cerebral small vessel disease, highlighting the fact that apathy can predict future dementia risk in these patients. https://jnnp.bmj.com/content/91/9/953

Sep 28,2020 08:07

15. Performance validity tests - Their role in neuropsychology assessments

Dr Laura Mc Whirter joins our podcast editor Colin Mahoney to discuss her recent systematic review of performance validity tests used across a range of neurological and psychiatric disorders. Are these tests useful and which conditions are the most likely to be helpful in. Join us to find out. https://jnnp.bmj.com/content/91/9/945

Sep 14,2020 12:29

16. Parkinson’s disease: etiopathogenesis and treatment

Prof Joseph Jankovic, Distinguished Chair in Movement Disorders, Baylor College of Medicine joins Podcast editor Colin Mahoney.Prof Jankovic provides a historical look back on the key developments in our understanding of the causes of Parkinson's disease and key treatments. https://jnnp.bmj.com/content/91/8/795

Aug 18,2020 24:02

17. Outcome measurement in functional neurological disorder a systematic review and recommendations

Dr Timothy Nicholson joins Podcast editor Colin Mahoney to discuss their recent systematic review of outcome measures used across the spectrum of functional neurological disorders. As well as identifying key domains for assessment he also discusses the challenges and future directions in developing more rigorous validated outcome measures for these increasingly recognised disorders. https://jnnp.bmj.com/content/91/6/638

Jul 20,2020 12:41

18. Clinical profiles of patients with dementia and chronic traumatic encephalopathy

Dr Christian Lobue, lead author joins Podcast Editor Colin Mahoney to discuss his original research which examines the clinical, neuropsychological and neuropsychiatric features of those with confirmed chronic traumatic encephalopathy (CTE) at autopsy. He compares the features with patients with CTE and those with Alzheimer's disease. https://jnnp.bmj.com/content/91/6/586

Jun 22,2020 16:23

19. Visual hallucinations in neurological and ophthalmological disease

Prof John O'Brien (University of Cambridge) and Dr Dominic Ffytche (Kings College London) join Dr Colin Mahoney (Podcast Editor)Visual hallucinations have complex origins and can have significant impact on patients. The recent UK based SHAPED consortium has aimed to design a common framework for assessment, management and research in this area. John O'Brien and Dominic Ffytche discuss disorders which cause visual hallucinations as well as their pathobiology and management in this Podcast: https:

May 27,2020 22:08

20. Primary Lateral Sclerosis: new consensus criteria

Prof Martin Turner, University of Oxford, joins Dr Colin Mahoney to discuss the newest consensus clinical criteria to aid in the diagnosis of Primary Lateral Sclerosis. This will enable neurologists to make the diagnosis sooner and will be important in the design of future treatment trials. https://jnnp.bmj.com/content/91/4/373

May 12,2020 14:04

21. Neurology in the time of COVID - 19

Dr Hadi Manji joins Colin Mahoney to discuss the recent paper by Liu and colleagues as well as providing a commentary on how COVID-19 may impact the nervous system and steps to mitigate this. He also discusses the impact of COVID-19 in delivering care at the National Hospital for Neurology and Neurosurgery, located in one of the new epicentres for this disease. https://jnnp.bmj.com/content/early/2020/04/20/jnnp-2020-323414

May 04,2020 15:18

22. Lithium: a slow burner

Prof Andrew Lees, Professor of Neurology National Hospital for Neurology and Neurosurgery. Colin Mahoney JNNP Podcast EditorAs part of our 2020 Vision centenary Prof Andrew Lees reviews how Lithium (eventually) became established in the treatment of psychiatric illness, reviewing the 1954 paper by Schou and colleagues.https://jnnp.bmj.com/content/jnnp/91/4/335.full

Apr 20,2020 20:49

23. Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia

Colin Mahoney, JNNP Podcast editor, is joined by Dr Jonathan Rohrer, MRC Clinician Scientist, Dementia Research Centre, UCL Institute of Neurology. Carolin Heller, Dementia Research Centre and UK Dementia Research Institute. to discuss how increased levels of GFAP may be used to detect advancing neurodegeneration and clinical change in those with Progranulin associated Frontotemporal Dementia. https://jnnp.bmj.com/content/91/3/263

Mar 26,2020 13:40

24. Multifocal motor neuropathy: controversies and priorities

Prof Bruce Taylor, Menzies Institute for Medical Research, University of Tasmania and Dr Colin Mahoney JNNP Podcast editorProf Bruce Taylor joins our podcast editor Colin Mahoney to discuss recent advances in the diagnosis and management of multifactorial neuropathy. They discuss the current state-of-the art on pathogenesis, new diagnostic approaches and management. https://jnnp.bmj.com/content/91/2/140.info

Mar 05,2020 14:13

25. Multiple Systems Atrophy: the nature of the beast revisited

As part of our 2020 Vision Series reviewing the most seminal papers in JNNP's past Prof Niall Quinn, joins Colin Mahoney to discuss his 1989 paper which provided the first clinical criteria for MSA. He discusses how the last 30 years of science has shaped this original work, and he also shares his experiences of his mentor Prof David Marsden who previously served as the editor of JNNP. https://jnnp.bmj.com/content/91/1/3

Feb 12,2020 13:48

26. Employment and MS - a patient’s perspective

Sharon Roman, a patient advocate who suffers with Multiple Sclerosis, discusses the complexities of measures of disease activity and employment in MS. https://jnnp.bmj.com/content/91/1/5

Jan 15,2020 12:34

27. Approaches to Chemotherapy induced peripheral neurotoxicity

Dr Susanna Park joins Colin Mahoney to discuss neurophysiological, imaging and other methods to study an increasingly recognised problem of chemotherapy induced peripheral neurotoxicity. Dr Park outlines the pathology and current techniques to diagnose and monitor this problem, and outline new areas of research as well as recommendations from the Toxic Neuropathy Consortium to improve clinical care and research in this area.https://jnnp.bmj.com/content/90/12/1361

Dec 02,2019 09:03

28. Neural circuitry of anxiety

Dr Oliver Robinson joins Colin Mahoney to discuss the neural circuitry of anxiety, outlining our current understanding the anatomical basis for anxiety, as well as paradigms used to explore the shared circuits which lead to pathological levels of anxiety. Dr Robinson also outlines the future research goals in this important area.https://jnnp.bmj.com/content/90/12/1353

Nov 18,2019 18:46

29. Dementia after traumatic brain injury

Dr Neil Graham and Prof David Sharp, from Imperial College London, discuss the interaction between traumatic brain injury and dementia. They outline the epidemiology, pathogenesis and emerging biomarkers in an area which is seeing increased attention. Read the full paper here: https://jnnp.bmj.com/content/90/11/1221.long

Oct 30,2019 20:19

30. Mindfullness in multiple sclerosis

Dr Robert Simpson (University of Glasgow, UK) discusses the merits and limitations of mindfullness based treatments for mental well-being in Multiple Sclerosis (MS). Read the full paper here: https://jnnp.bmj.com/content/90/9/1051

Sep 27,2019 17:13

31. CIDP an update

Professor Helmar Lehmann (University Hospital of Cologne) provides an update on Chronic inflammatory demyelinating polyneuropathy (CIDP) and discusses recent advances in diagnosis and treatment. Read the full paper here: https://jnnp.bmj.com/content/90/9/981.long

Sep 11,2019 09:58

32. Movement disorders and seizures

Elizabeth Highton (podcast editor) is joined by Professor Alfonso Fasano (Toronto Western Hospital, Ontario, Canada) to discuss the overlapping phenomenology and diagnostic challenges in movement disorders and seizures. Read the paper here: https://jnnp.bmj.com/content/90/8/920.long

Aug 15,2019 18:09

33. The role of functional neuroimaging in functional neurological disorders

Dr. David Perez (Massachusetts General Hospital, USA) speaks with JNNP Podcast Editor, Elizabeth Highton about stepwise functional connectivity, a novel brain imaging technique, and how it might help us better understand the biology of functional neurological disorders. Read this month's Patient's Choice article here: https://jnnp.bmj.com/content/90/8/929

Jul 31,2019 12:57

34. Emotional processing in functional neurological disorder (FND)

Dr. Susannah Pick (King’s College London, UK) discusses emotional processing in functional neurological disorder, and how further understand of emotional processing deficits may help contribute to a unified explanatory model for FND.

Jun 12,2019 12:13

35. Can cocoa help with fatigue in MS

Dr Shelly Coe (Oxford Brookes University, Oxford) discusses a new randomized control trial looking at the use of cocoa for management of fatigue in multiple sclerosis. Read the full paper here: https://jnnp.bmj.com/content/90/5/507

May 28,2019 07:00

36. Neurorehabilitation in chronic stroke

JNNP Associate Editor, Professor Nick Ward (Queens Square, London) tells us all about the Queen Square Upper Limb Neurorehabilitation programme, and specifically, what clinical gains in chronic stroke patients were observed after high intensity neurorehabilitation. Read the full paper here: https://jnnp.bmj.com/content/90/5/498

May 08,2019 12:48

37. The real patient value

The JNNP recently launched the patient editorial board in an effort to drive more meaningful patient outcomes. One of our newly appointment board members, Sharon Roman (Vancouver Canada) discusses why she believes the patient perspective leads to better healthcare and what the patient partnership looks like at the JNNP. Read Sharon’s editorial here: https://jnnp.bmj.com/content/jnnp/90/4/371.full.pdf

Apr 18,2019 12:44

38. Medical conferences - what do we get out of them?

A special edition podcast - based on an essay discussing the value of medical conferences and whether it is time to consider what is gained from these events, and for whom. Emeritus Professor Michael Swash (The Royal London Hospital and Barts and the London School of Medicine) joins Elizabeth Highton to discuss the merits of the medical congress. Read the commentary here: https://jnnp.bmj.com/content/early/2018/10/18/jnnp-2018-319248

Apr 04,2019 09:30

39. Oral immunotherapies in MS a comparison of efficacy.

Associate Professor Tomas Kalincik (University of Melbourne, Australia) discusses oral immunotherapies, and what we know about the effects of these treatments on patient relapse and disability. Read the full paper here: https://jnnp.bmj.com/content/early/2019/01/12/jnnp-2018-319831

Mar 25,2019 12:13

40. Therapeutic trial design in frontotemporal dementias

Editor’s Choice: Associate Professor Dr Mario Masellis (University of Toronto) and Assistant Professor Philippe Desmarais (University of Montreal) discuss the complexities of designing trials in frontotemporal dementia (FTD) and how precision medicine might help disentangle this Gordian knot in the future. Read the full paper here: https://jnnp.bmj.com/content/jnnp/early/2018/11/01/jnnp-2018-318603.full.pdf

Mar 20,2019 13:06

41. Do genes affect age of onset in ALS?

Professor Ammar Al-Chalabi (King’s College London, London, UK) joins Elizabeth Highton (podcast editor) to discuss motor neurone disease, also known as amyotrophic lateral sclerosis or ALS, a rapidly progressive illness resulting from the degeneration of both upper and lower motor neurons. Studies have shown that age of onset is younger in people with a family history – but it this due to a heightened knowledge of the disease or due to genetics lowering the age of onset? Read the full paper here

Mar 11,2019 09:50

42. The lifetime risk of common neurological disorders in the elderly population

We have a good understanding of our risk of developing cancer or heart disease – but what do we know about the risk of developing a common neurological disorder in later-life? Dr. Silvan Licher (Department of Epidemiology, University Medical Center Rotterdam, Netherlands) discusses the lifetime risk of developing dementia, stroke, and Parkinson’s disease, and how we need to better prioritise preventive interventions. Read the full paper here: https://jnnp.bmj.com/content/jnnp/90/2/148.full.pdf

Feb 18,2019 06:17

43. PMA and PLS: are they really restricted phenotypes?

Dr. Michael van Es (University Medical Center Utrecht, Netherlands) examines whether cognitive and behavioural changes can be seen across the motor neurone disease spectrum, and how this helps inform our understanding of these as multidimensional diseases. Read the editorial commentary by Professor Martin Turner here: https://jnnp.bmj.com/content/90/2/122

Feb 04,2019 08:57

44. Statins and the risk of recurrent intracerebral haemorrhage (ICH) – what does the evidence say?

Do statins increase the risk of intracerebral haemorrhage (ICH) in patients with a previous stroke? Professor David Werring (Stroke Research Centre, UCL Institute Of Neurology, Queen Square, London, UK) joins Elizabeth Highton (JNNP podcast editor) for the first JNNP podcast of 2019. Read the full paper here: https://jnnp.bmj.com/content/90/1/75

Jan 21,2019 12:02

45. Functional impairment and improvement

Elizabeth Highton (podcast editor) hosts the final JNNP podcast for 2018, an episode on functional improvement after stroke (Dr. Aravind Ganesh, University of Oxford, UK- https://jnnp.bmj.com/content/89/12/1301) and cognitive impairment in functional neurological disorders (Dr. Jeremy Isaacs (St George’s University and Hospital, London, UK - https://jnnp.bmj.com/content/89/12/1308).

Dec 10,2018 28:56

46. Can computational models help us understand complex movement disorders?

Professor Mark Humphries (University of Nottingham, UK) discusses how computational modelling could be a crucial tool in untangling the complexities of diseases like Parkinson’s disease. Can this type of modelling help us understand causes, and eventually lead to treatment options? Read the full paper here: https://jnnp.bmj.com/content/early/2018/04/17/jnnp-2017-315922.long

Oct 29,2018 11:52

47. Idiopathic intracranial hypertension: guidelines for diagnosis and management

In collaboration with many different specialists, professions and patient representatives, Mollan et al (2018) have developed the first ever guidelines for the investigation and management of idiopathic intracranial hypertension (IIH). Senior author, Dr Alexandra Sinclair (University of Birmingham) discusses these with the JNNP podcast editor, Elizabeth Highton. Read the full guidelines here: https://jnnp.bmj.com/content/89/10/1088 Access the Practical Neurology infographic summary here: https

Oct 08,2018 14:55

48. Nusinersen for SMA

Elizabeth Highton (JNNP Podcast Editor) speaks with Dr. Michelle Farrar (University of New South Wales) discussing nusinersen, the first disease-modifying therapy for spinal muscular atrophy type 1 (SMA). https://jnnp.bmj.com/content/89/9/937

Aug 29,2018 10:20

49. Expanding clinical spectrums in both Kennedy’s disease and poststroke syndromes

Dr. Carlo Rinaldi (University of Oxford) discusses how the traditional view of Kennedy’s disease is evolving, to extend beyond pure motor symptoms. What non-motor features may be present in Kennedy's, and crucially how do they impact on patient's care and management? Read the full paper here: https://jnnp.bmj.com/content/89/8/808. Helle Stangeland and Vaughan Bell join us to discuss a much overlooked clinical syndrome in stroke: poststroke psychosis. Just how often does it occur and how can it

Aug 06,2018 28:47

50. The use of cannabis in epilepsy, and surgery for tremor

Around 20-30% of patients with epilepsy can demonstrate resistance to commonly used medications. Cannabidiol (CBD) is a compound found in cannabis, which can be used for the treatment of epilepsy, shown to actively modulate seizure activity. Dr Emily Stockings (University of New South Wales in Sydney, Australia ) outlines how CBD can be helpful for patients with drug-resistant epilepsy. Read the full paper here: http://jnnp.bmj.com/content/89/7/741.longDr Georg Kaji (Kantonsspital, St.Gallen, S

Jul 02,2018 23:28

51. Epilepsy an evidence update

Is the mesial temporal lobe the seat of psychosis in epilepsy? James Allebone (University of Melbourne, Australia) discusses what neuroimaging can tell us about psychosis in epilepsy. Read the paper here: http://jnnp.bmj.com/content/89/6/611.Patients with epilepsy are often not permitted to drive, but can this change after surgery? Professor John Duncan (University College London, UK) provides a crucial update on measuring relative risk of seizures following epilepsy surgery, and how this impact

May 31,2018 20:52

52. Evolution or revolution? Should we re-think clinical practice?

Do old habits of screening for potassium channel antibodies stand up to scrutiny? Should clinical neurologists focus on screening for LGI1 and CASPR2 antibodies? Professor Sarosh Irani (John Radcliffe Hospital, Oxford) discusses antibody testing, and whether recent evidence calls for a revolution of clinical practice. Read the full paper here: http://jnnp.bmj.com/content/89/5/526.In the second half of this podcast, Professor Ryuji Kaji (Tokushima University, Japan) discusses the pathogenesis of

Apr 30,2018 18:31

53. The Use of Frankincense Extract In MS

Patients with multiple sclerosis (MS) often show interest in complementary and alternative medicines, particularly when on long-term anti-inflammatory treatments. Is frankincense a safe and tolerable treatment? Dr Klarissa Stürner (Christian-Albrechts University, Kiel) discuss the pilot trial (conducted at the Institute of Neuroimmunology and Multiple Sclerosis, Hamburg).Read the paper here: http://jnnp.bmj.com/content/89/4/330.longRead the editorial here: http://jnnp.bmj.com/content/89/4/327

Apr 04,2018 16:55

54. A new questionnaire to measure quality of life in inflammatory neuropathies

Quality of life (QoL) is one of the most important outcomes for chronic diseases, although it remains remarkably difficult to quantify. Dr. Thomas Draak (Maastricht University, The Netherlands) discusses his new questionnaire, and how it aims to capture the patient’s perspective. Read the full paper here:http://jnnp.bmj.com/content/jnnp/early/2017/11/24/jnnp-2017-316634.full.pdf

Mar 07,2018 08:08

55. Marriage and a reduced risk of dementia

Recent research has indicated that being married is associated with a reduced risk of dementia. What is it about marriage? Dr Andrew Sommerlad (University College London) discusses this question and more. Read the full paper here: http://jnnp.bmj.com/content/early/2017/10/30/jnnp-2017-316274

Feb 28,2018 14:48

56. Anti-inflammatory approaches to stroke prevention; monitoring disease progression in ALS

Atherosclerosis is a major contributor to increased risk of stroke. Our patient’s choice, Professor Peter Kelly (University College Dublin, Dublin, Ireland) discusses the evidence base implicating inflammation as a key process in the pathogenesis of atherosclerosis, leading to thromboembolic events. Read the full paper here: http://jnnp.bmj.com/content/89/2/211.How do you measure disease progression in a highly variable and heterogeneous clinical population, such as amyotrophic lateral sclerosis

Feb 08,2018 31:00

57. Nodes and paranodes; alternative treatments in MS

People with multiple sclerosis (MS) use complementary and alternative treatments (CAM), but what does the evidence say? Patient’s Choice, Professor Bruce Taylor (University of Tasmania) discusses the modern evidence for CAM use. Read the paper here: http://jnnp.bmj.com/content/89/1/34.What roles do nodes and paranodes play in complex neuropathies? Dr Simon Rinaldi (University of Oxford) summarises the involvement of these specialised domains as this month’s Editor’s Choice. Read the full paper h

Jan 26,2018 18:29

58. Pathophysiology of functional neurological disorder

Despite the prevalence of the disease, neurologists and psychiatrists can be wary of treating patients with functional neurological disorder (FND). Assistant Professor David Perez (Massachusetts General Hospital, USA) discusses how FND sits between neurological and psychiatric disciplines, the relationship between poor health status and affective symptoms, and associations with grey matter volumetric profiles. Read more here: http://jnnp.bmj.com/content/88/12/1052.

Dec 13,2017 11:15

59. Is methamphetamine use linked to stroke in young adults?

Is methamphetamine use linked to strokes in young adults? Important clinical implications discussed by Dr. Julia Lappin (University of New South Wales) in this month’s JNNP podcast.http://jnnp.bmj.com/content/88/12/1079

Nov 28,2017 09:54

60. Cerebral Amyloid Angiopathy: New Insights For Clinical Practice

Cerebral amyloid angiopathy (CAA) has been gaining attention over the past few years, thanks to increased research in the field. Professor David Werring (UCL Institute of Neurology, Queens Square, London) discusses the recent advances in biomarkers analysis, as well as providing an overview of the clinical spectrum of CAA. Read the full paper here: http://jnnp.bmj.com/content/early/2017/08/26/jnnp-2016-314697

Nov 08,2017 18:35

61. Cortical Influences in ALS

Professor Emeritus Andrew Eisen (University of British Columbia, Canada) discusses the theory of corticofugal primary in amyotrophic lateral sclerosis. ALS can be viewed as a primarily human disorder mediated by corticomotorneuronal pathways, originating in the cerebral cortex. Read the full paper here: http://jnnp.bmj.com/content/88/11/917.

Oct 31,2017 20:58

62. Intravenous immunoglobulin in CIDP

Can IViG be used as a longer term maintenance therapy for CIDP patients? JNNP Associate Editor, Professor Satoshi Kuwabara (Chiba University Hospital, Japan) joins us for this podcast, discussing recent trial results and their implications for patient care. Read the full paper here: http://jnnp.bmj.com/content/88/10/832

Oct 23,2017 11:40

63. Complex inherited neuropathies: a new approach to diagnosis?

Professor Mary Reilly (Institute of Neurology, Queens Square, London) discusses how complex inherited neuropathies can be a daunting diagnosis for clinicians. However, through exciting advances in next generation sequencing and knowledge of distinct syndromic categories, a new diagnostic approach emerges. Her review and her interview provide excellent over of this new approach, and how it may serve as a resource for clinicians. Link to paper here: http://dx.doi.org/10.1136/jnnp-2016-313960.

Oct 18,2017 18:22

64. Cerebellum and neurodegeneration; autoantibodies and psychological development in children

The September 2017's JNNP podcast is a double episode.The first conversation is with Professor Michael Hornberger from the Norwich Medical School, University of East Anglia, UK. The cerebellum is often overlooked when looking at neurodegenerative diseases, a practice which Professor Hornberger and his team are challenging. Their recent JNNP paper looks at patterns of grey matter atrophy in the cerebellum across neurodegenerative diseases. What they found may surprise some listeners.Read the pape

Sep 04,2017 15:37

65. Time Matters - part 2: how the real costs of multiple sclerosis are being concealed

“Take a comprehensive economic approach to evaluating treatment cost-effectiveness in MS”. Jacqueline Palace (Consultant Neurologist, Nuffield Department of Clinical Neurosciences, University of Oxford) and Ruth Geraldes (Neurologist, Department of Clinical Neurosciences, University of Oxford) examine the economic burden of multiple sclerosis, which was debated at the international roundtable “Time Matters in MS”, organised by the BMJ and the JNNP on World MS Day 2017, in Lisbon.Read more, watch

Aug 07,2017 11:21

66. Survival and cause of death in Multiple Sclerosis

There has been an increase in life expectancies for the general population over the last few decades. A similar trend has also been identified in patients with Multiple Sclerosis (MS). To investigate this trend further, Dr Lunde and colleagues, from the Norwegian Multiple Sclerosis Competence Centre, investigated survival and cause of death in an MS cohort. Dr Lunde discusses the findings with Elizabeth Highton in the August 2017's JNNP podcast. Download the paper here: http://jnnp.bmj.com/cont

Jul 19,2017 13:23

67. Time Matters - part 1: delay is “expensive” in all aspects of multiple sclerosis

Professor Emeritus Alastair Compston (University of Cambridge) discusses with JNNP’s Publisher Janet O'Flaherty the issues raised by the discussion “Brain health matters in multiple sclerosis” (MS), which was part of the international roundtable “Time Matters in MS”, organised by the BMJ and the JNNP on World MS Day 2017, in Lisbon.Read more, watch the videos and access all the information about the event on the JNNP's website special page: http://jnnp.bmj.com/pages/time-matters-in-ms/.“Time Mat

Jul 10,2017 11:25

68. Seven tesla MRI In Neurodegenerative Dementias

MRI is an important clinical tool to study dementia symptoms in vivo. However, certain pathologies (microbleeds, plaques, tangles) can evade current imaging techniques. Seven tesla (7T) MRI provides a potentially exciting new opportunity to visualise these pathologies in vivo. Dr. Elizabeth McKiernan (University of Cambridge) discusses the literature around 7T MRI, and its scope in neurodegenerative dementias.Read the review in the JNNP website: http://jnnp.bmj.com/content/early/2017/03/03/jnnp-

Jun 16,2017 11:25

69. Conversational Laughter In Dementia

Laughter serves a fundamental social purpose, the appropriate use of which requires recognition of social norms. So what happens when these interpersonal abilities are affected, such as in the frontotemporal dementias? Does use of laughter change too? Dr Peter Pressman (Rocky Mountain Alzheimer’s Disease Center, University of Colorado, USA) talks to Elizabeth Highton about observing conversational laughter in frontotemporal dementia. This paper was chosen for this month’s Editor’s Choice and can

May 05,2017 13:52

70. Narrative and Neurology: The Andrew Lees Experiment

Professor Andrew Lees discusses his book "Mentored by a Madman: The William Burroughs Experiment" with Dr Sean O’Sullivan and Elizabeth Highton. Andrew speaks to the importance of looking beyond one’s area of expertise for mentorship, the relationship between art and science in neurology, Parkinson's disease and how William Burroughs played an unlikely role in his own medical career. You can read Sean O’Sullivan’s review of the book on the JNNP website: http://jnnp.bmj.com/content/88/3/280.

Apr 06,2017 32:54

71. April 2017: deconstructing dilemmas in Amyotrophic Lateral Sclerosis and Guillain-Barré Syndrome

Both patient and editor's choices are discussed in this monthly episode of the JNNP podcast.The clinical care of patients with Guillain-Barré syndrome (GBS) can often be complex; a disease with a highly variable clinical course. Professor Bart Jacobs, from the Department of Neurology at Erasmus Medical Centre (Rotterdam) provides an overview of some of the dilemmas that may arise when treating patients with GBS. The full article: http://jnnp.bmj.com/content/88/4/346.In the second part of this po

Mar 27,2017 18:14

72. Zika virus and Guillain-Barré Syndrome: what do we know?

There is concern that, despite being a rare complication of the Zika virus, we could see a steady rise in the number of cases of Guillain-Barré Syndrome (GBS). In preparation for this, it is important that clinicians are able to appropriately identify and differentiate between Zika-associated GBS and other neurological disorders. In this podcast, Professor Antonino Uncini (University ‘G’ d’Annunzio’, Chieti, Italy) discusses Guillain-Barré Syndrome (GBS) and it’s associations with Zika virus, as

Mar 13,2017 15:01

73. Immunomodulatory therapy in advanced multiple sclerosis

Could currently available immunomodulatory therapies modify disability trajectories in patients with moderately advanced and advanced multiple sclerosis (MS)? Tomas Kalincik, Department of Medicine, University of Melbourne, Australia, discusses the findings from the MSbase cohort study with Elizabeth Highton.Read the full article here: http://jnnp.bmj.com/content/88/3/196.

Feb 13,2017 14:05

74. The relationship between orthostatic hypotension and cognitive impairment in α-synucleinopathies

Dr Mario Masellis and Dr. Sean Udow from the Sunnybrook Health Sciences Centre, University of Toronto, Canada, look at the potential association between orthostatic hypotension and cognitive impairment in α-synucleinopathies such as Parkinson’s disease, dementia with Lewy bodies and multiple system atrophy. Read the review published by JNNP here: http://jnnp.bmj.com/content/early/2016/09/09/jnnp-2016-314123.abstract.

Nov 30,2016 11:06

75. A clinical tool for predicting survival in motor neurone disease

Elizabeth Highton spoke to Professor Ammar Al-Chalabi from King’s College London about the development of a simple and clinically useful graphical model of predicting survival for motor neurone disease (MND) patients.Read the article here: http://jnnp.bmj.com/content/early/2016/07/26/jnnp-2015-312908.abstract

Nov 30,2016 08:31

76. Latitude and disease severity in Multiple Sclerosis

Elizabeth Highton and Prof. Bruce Taylor discuss higher latitudes and its association with earlier age of onset of Multiple Sclerosis (MS).The international study, published by the JNNP, links latitude to the age at which symptoms of MS first start. Each 10ᵒ increase in latitude is associated with a 10 month earlier onset of symptoms among those of European descent.Read the full article here: https://goo.gl/BmHXFo.

Nov 15,2016 11:20

77. Do your kids play rugby? Risks for rugby union players from repeated concussions

Associate Editor of JNNP Alan Carson interviews Tom McMillan, Professor at the Institute for Health & Wellbeing, University of Glasgow, UK, about the paper "Long Term Health Outcomes after Exposure to Repeated Concussion in Elite Level Rugby Union Players".Despite a high number of concussions in retired male Scottish international rugby players, the researchers didn’t find differences in mental health, social or work functioning late after injury. However, subtle group differences were detected

Nov 07,2016 17:53

78. Genetics and the clinical course of multiple sclerosis

Professor Bruce Taylor and Elizabeth Highton discuss how certain genetic risk variants may predict the clinical course and progression of Multiple Sclerosis.This podcast relates to the Patient Choice paper published in the JNNP November 2016 issue and is accessible here: http://jnnp.bmj.com/content/87/11/1204.full.

Oct 18,2016 10:32

79. Is it time to focus on the common pathways linking neurodegenerative diseases?

Dr. Rebekah Ahmed talks about her recent JNNP review: Neuronal network disintegration and the common pathways linking neurodegenerative diseases.Dr. Ahmed and colleagues critically evaluate a new approach to neurodegenerative disease, a focus on phenotypic presentation opposed to syndromic diagnosis. Via collaborative efforts, should we be looking at the commonalities between the neurodegenerative diseases?Read the full article here: http://jnnp.bmj.com/content/early/2016/05/12/jnnp-2014-308350.

Oct 13,2016 13:44

80. October 2016 Edition: long-term outcomes after stroke; hereditary and inflammatory neuropathies

In this JNNP podcast, Elizabeth Highton speaks with Dr. Siobhan Crichton and Dr. Benjamin Bray about their study looking at patient outcomes up to 15 years after stroke. Read their full paper here: http://jnnp.bmj.com/content/early/2016/07/22/jnnp-2016-313361.full. She is also joined over Skype by Professor Yusuf Rajabally who discusses his review examining the distinction between hereditary and inflammatory neuropathies and the instances whereby the distinction between the two is less clear. Hi

Sep 22,2016 18:39

81. Selective vulnerability in clinical variants of Alzheimer’s Disease

Elizabeth Highton spoke with Professor Henrik Zetterberg from Sahlgrenska University in Sweden. They discuss his recent JNNP review looking at clinical variants of Alzheimer's Disease and whether selective vulnerability in the nervous system may help explain some of the different phenotypic expressions of the same disease.

Aug 30,2016 16:02

82. Smoking: a negative prognostic for survival in motor neurone disease patients

Elizabeth Highton is joined by Prof. Adriano Chio to talk about his study:Influence of cigarette smoking on ALS outcome: a population-based study.His large population-based cohort study of patients with amyotrophic lateral sclerosis (ALS), commonly known as motor neurone disease, demonstrated that smoking is linked to their shorter survival and smokers also tended to be younger when the symptoms first appeared.Read the full article here: http://jnnp.bmj.com/content/early/2016/08/19/jnnp-2016-313

Aug 19,2016 10:22

83. Review: Amyotrophic Lateral Sclerosis and Motor Neuron Syndromes in Asia

In this podcast, Dr Nortina Shahrizaila, a neurologist from the University of Malaya, talks about her review regarding Amyotrophic lateral sclerosis and motor neuron syndromes in Asia. She discusses with Elizabeth Highton what is known of ALS in Asia from an epidemiological perspective through to disease characterisation and particular phenotypes which can be seen in Asian patients. They also discuss the Pan-Asian Consortium for Treatment and Research in ALS (PACTALS), whereby clinicians and res

Jul 27,2016 14:52

84. Automated brain volumetrics in multiple sclerosis, plus migraine and psychiatric co-morbidities

In this July podcasts, Associate Professor Michael Barnett explains the details of his short report comparing Structural Image Evaluation using Normalisation of Atrophy-Cross Sectional (SIENAX) to Neuroquant and MSmetrix for assessment of cross-sectional Whole Brain Volume (WBV) in patients with Multiple Sclerosis (MS). Michael Barnett, from the Sydney Neuroimaging Analysis Centre at the Brain and Mind Centre, University of Sydney, discusses with Elizabeth Highton the potential clinical utility

Jun 30,2016 21:36

85. Coffee consumption and multiple sclerosis

Can coffee impact on the health of neurons? And what are the effects of its consumption on the risk of developing multiple sclerosis?These are some of the questions Dr Ellen Mowry answers in this podcast. She is an Associate Professor of Neurology at the Johns Hopkins Hospital and one of the authors of the study, “High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies”, which was selected as Patient choice article for the May issue o

Jun 07,2016 11:05

86. June Edition: Parkinson’s disease and the rate of ALS progression

In this podcast, Elizabeth Highton investigates the details of two studies selected for the June 2016 edition of JNNP.Professor Steve Vucic, from the Department of Neurology at Westmead Hospital, Sydney, talks about the details of his study, which concludes that the rate of ALS progression appears to be a simple and sensitive clinical prognostic biomarker in the disease that could be potentially utilised in clinical practice and future therapeutic trials.The paper “Rate of Disease Progression: A

May 24,2016 22:00

87. Sudden Unexpected Death in Epilepsy: basic mechanisms and implications for prevention

In this podcast, Dr Brian J Dlouhy explains the mechanisms behind sudden unexpected death in epilepsy (SUDEP), one of the most common cause of death in patients with intractable epilepsy.“Sudden unexpected death in epilepsy: basic mechanisms and clinical implications for prevention” was selected for the April 2016 Patient Choice of the JNNP.Read the full review here: http://jnnp.bmj.com/content/87/4/402.full.

Apr 08,2016 09:53

88. Re-evaluating the treatment of acute optic neuritis

In this podcast, Professor Elliot Frohman discusses the treatment of acute optic neuritis and its connection with multiple sclerosis.Elliot Frohman is Professor of Neurology and Neurotherapeutics and Ophthalmology and Director of the Multiple Sclerosis and Neuroimmunology Program, at the University of Texas. Read the full paper here:http://jnnp.bmj.com/content/early/2014/10/29/jnnp-2014-308185.full

Feb 10,2016 19:17

89. BNPA 2015: Spatial Neglect

Kieran O'Driscoll, Neuropsychiatrist, Manchester, speaks to Giuseppe Vallar, Professor of Psychobiology and Physiological Psychology, University of Milano-Bicocca, about spatial neglect.This podcast was recorded at the 2015 BNPA AGM.

Jun 08,2015 05:27

90. BNPA 2015: New theories of memory systems and networks

Chris Butler speaks to Adam Zeman about new theories of memory systems and networks.This podcast was recorded at the 2015 BNPA AGM.

Jun 08,2015 10:27

91. BNPA 2015: Phantom phenomena

David Linden, neuropsychiatrist, Cardiff, Wales, talks to Peter Brugger, Department of Neurology, University Hospital Zurich, about phantom phenomena.This podcast was recorded at the BNPA 2015 AGM.

Feb 24,2015 05:22

92. Clinical neurology: why this still matters in the 21st century

David Nicholl argues that even with the tremendous advances in diagnostic neuroimaging that the clinical skills involved in clinical neurology remain key. In a recent JNNP review he writes that recent audits suggest that large numbers of patients are failing to be assessed properly with a risk of patient harm, costly, unnecessary or inappropriate investigations, or delayed diagnosis. In this podcast Matthew Kiernan asks Dr Nicholl, Department of Neurology, City Hospital, Birmingham, why patients

Jan 27,2015 11:32

93. Imaging outcomes for trials of remyelination in multiple sclerosis

Trials of potential neuroreparative agents are becoming more important in the spectrum of multiple sclerosis research. Appropriate imaging outcomes are required that are feasible from a time and practicality point of view, as well as being sensitive and specific to myelin, while also being reproducible and clinically meaningful. Conventional MRI sequences have limited specificity for myelination. With colleagues Shahrukh Mallik, Department of Neuroinflammation, NMR Research Unit, Queen Square Mu

Dec 11,2014 11:56

94. BNPA 2014: Oxytocin and social cognition

Individual differences in our capacity to read other people’s emotions and to remember faces we have seen before are highly variable in the general population. Some people are super-recognizers; others have difficulty remembering their own family members. Such abilities are also highly heritable, implying our genetic makeup exerts an important influence. But what genes are involved in social perception? Where do they act when our brains process social signals? What happens if the social percepti

Dec 02,2014 06:57

95. BNPA 2014: Schizophrenia and cognition

Cognitive impairment is generally considered an important facet of the schizophrenia syndrome but how fundamental is it? In this podcast Alan Carson discusses the question with Eileen Joyce, Consultant Neuropsychiatrist at the National Hospital for Neurology and Neurosurgery. She argues that there is a limited general resource in schizophrenia that constrains the performance of a wide range of specific cognitive functions and underlies the development of psychotic symptoms as well as determining

Dec 02,2014 08:06

96. Advances in epilepsy surgery

Exciting recent and forthcoming advances will impact on the surgical management of epilepsy in the near future.Mark Nowell and John Duncan, both Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, have conducted a review on where the treatment is headed, and discuss the three broad directions where they see the next major advances occurring.Read the full paper, for free: http://goo.gl/f35bPF

Nov 27,2014 17:51

97. Brain atrophy and disability progression in multiple sclerosis patients

Dr Robert Zivadinov, Department of Neurology, School of Medicine and Biomedical Sciences, Buffalo Neuroimaging Analysis Center, discusses his paper which aimed to identify MRI biomarkers associated with long-term disability progression in patients with multiple sclerosis (MS), and to define the rate of evolution of global, tissue-specific and regional atrophy in patients with MS over long-term.Read the full paper (for free): http://jnnp.bmj.com/content/85/10/1109.full

Oct 13,2014 11:24

98. BNPA 2014: Joint hypermobilty and autonomic hyperactivity

Chis Butler, MRC Clinician Scientist and Honorary Consultant Neurologist at the University of Oxford, talks to Jessica Eccles, MRC Clinical Research Training Fellow, Brighton and Sussex Medical School, about her work into joint hypermobilty and autonomic hyperactivity, and their relevance to neurodevelopmental disorders.Read the abstract: http://jnnp.bmj.com/content/85/8/e3.40.abstractThis podcast was recorded at the 2014 British NeuroPsychiatry Association AGM.

Sep 17,2014 05:13

99. BNPA 2014: Post-Ictal psychosis

Hugh Rickards, consultant in Neuropsychiatry and honorary reader in Neuropsychiatry at Birmingham University, talks to Georgy Pius, ST6 Trainee, North West Deanery, about his case-control study examining post-ictal psychosis.Read the abstract: http://jnnp.bmj.com/content/85/8/e3.39.abstractThis podcast was recorded at the 2014 British NeuroPsychiatry Association AGM.

Sep 17,2014 05:10

100. BNPA 2014: TREM2 variants and risk of dementia

Chris Butler, MRC Clinician Scientist and Honorary Consultant Neurologist at the University of Oxford, talks to Catherine Slattery, Clinical Research Associate, Institute of Neurology, about her work looking at TREM2 and associated risk of dementia.Read the abstract:http://goo.gl/SkJVXrThis podcast was recorded at the 2014 British NeuroPsychiatry Association AGM.

Sep 17,2014 04:48

101. Neurosurgical procedures for psychiatric illness

This month, how to safely and ethically carry out stereotactic surgery for psychiatric illness.Bart Nuttin, Department of Neurosurgery, University of Leuven, has put together pragmatic guidelines, with the input of international psychiatric and neurosurgical societies.Here he gives us an overview.Read the guidelines in full: http://jnnp.bmj.com/content/85/9/1003.full

Sep 17,2014 17:53

102. Can stress trigger Parkinson’s? And new criteria for frontotemporal dementia syndromes.

Does emotional stress trigger Parkinson's disease? Andrew Lees, Reta Lila Weston Institute of Neurological Studies, talks us through the evidence so far.And Glenda Halliday, Neuroscience Research Australia, and colleagues, have examined the clinical and pathological diagnostic implications of new criteria for frontotemporal dementia syndromes. She discusses the highlights.Read both the papers, for free:New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic impli

Aug 05,2014 36:54

103. HIV and multiple sclerosis: beginning to unravel a mystery

Julian Gold, professor in the department of neuroscience and trauma, Queen Mary, University of London, and senior staff specialist, Albion Centre, Prince of Wales Hospital, Sydney, discusses his paper which investigates whether or not HIV protects against developing MS.Read the paper, for free: HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study http://goo.gl/j0G3SR

Jul 02,2014 13:27

104. BNPA 2014: Neuropsychiatry of social knowledge and moral motivation

JNNP editor Alan Carson asks Roland Zahn, senior clinical lecturer, King's College London, about the neuroanatomy of moral behaviour, particularly his work into the neural mechanism of moral emotion in depression.This podcast was recorded at the 2014 British NeuroPsychiatry Association AGM.

Jun 24,2014 11:08

105. DBS in essential tremor, and genetic counselling for ALS

This month, genetic counselling for amyotrophic lateral sclerosis (ALS). Adriano Chiò, Turin ALS Expert Center, ‘Rita Levi Montalcini’ University of Turin, tells us what it can and can't do, who should have it, and how to go about it.And deep brain stimulation for essential tremor. Joseph Jankovic, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, explains what his study on long-term outcomes reveals.Read the papers:Genetic counselling in ALS: facts, uncertain

May 22,2014 22:34

106. Mortality and morbidity 15 years after hospital admission with mild head injury

Head injury is very common, and we know those admitted to hospital with a severe head injury have a high mortality rate in the proceeding year. However less is known about later mortality, and even less about late survival after mild head injury, which accounts for 95% of all head injuries.Tom McMillan, Institute of Health and Wellbeing, MVLS, University of Glasgow, and colleagues, have followed up patients 15 years after admission with a mild head injury, and recently published the results in J

Apr 30,2014 14:18

107. Informed decision making in MS, and the striatum in neurodegeneration

What's the role of the striatum, in changes in cognition and behaviour in neurodegeneration? Michael Hornberger, University of Cambridge, explains why it may be more pivotal than we currently think.And how best to support patients just diagnosed with multiple sclerosis, who are facing difficult decisions around their treatment? Sascha Köpke, University of Lübeck, discusses the results of his trial comparing two programmes.Read the papers, for free:Beyond and below the cortex: the contribution of

Apr 04,2014 29:38

108. BNPA special: Autoimmune encephalitis

Angela Vincent, emeritus professor of neuroimmunology at the University of Oxford, gives Adam Zeman, professor of cognitive and behavioural neurology, University of Exeter, an overview of autoimmune disorders of the central nervous system.This podcast is one of several recorded with the British Neuropsychiatry Association, more of which will be published over the next few months. For all the podcasts in this series, see: soundcloud.com/tags/bnpa%202014

Mar 14,2014 10:59

109. BNPA special: The prospects of a vaccine for Alzheimer’s disease

Adam Zeman, professor of cognitive and behavioural neurology, University of Exeter, asks James Nicoll, professor of neuropathology, University of Southampton, about the progress being made in preventative treatments for Alzheimer's.For more on early treatment for Alzheimer's, watch Nick Fox's talk on presymptomatic treatment for the dementias on JNNP's YouTube channel: http://goo.gl/95sVXBBoth this podcast and the Professor Fox's talk were recorded with with the British Neuropsychiatry Associati

Mar 13,2014 10:08

110. An unusual variant of Guillain–Barré syndrome, and dopamine dysregulation syndrome

This month, an unusual variant of Guillain Barre syndrome - the pharyngeal cervical brachial variant. Benjamin Wakeley, a consultant neurologist at the Gloucester Hospitals NHS Foundation trust talks through what clinicians need to know.Also, a look at an uncommon but difficult to resolve complication of Parkinson’s disease therapy - that of dopamine dysregulation syndrome. Robert Cilia, from the Parkinson Institute in Milan, discusses his paper examining the characterisation, management and lon

Mar 04,2014 25:57

111. BNPA special: Impulse control disorder in Parkinson’s

Kieran O'Driscoll, consultant neuropsychiatrist in Liverpool, talks to David Okai, a consultant in psychological medicine in Oxford and researcher at King's College London, discusses assessing and managing impulse control disorder in Parkinson's.This podcast is one of several recorded with the British Neuropsychiatry Association, more of which will be published over the next few months. For all the podcasts in this series, see: soundcloud.com/tags/bnpa%202014See also:Impulse control disorder in

Mar 03,2014 08:41

112. Diagnosing and treating functional symptoms

February's JNNP is a neuropsychiatry special issue, with papers on a broad range of disorders which lie between neurology and psychiatry. Associate editor Alan Carson discusses the contents, and the thinking behind the edition.To accompany the issue, JNNP and the Association of British Neurologists convened a roundtable of experts to discuss, and advise on, diagnosing and treating functional symptoms. Dr Carson takes part in this, along with:Kailash Bhatia, professor of neurology, Institute of N

Jan 10,2014 27:59

113. Solving the case, making the diagnosis: Neurology and detective writing

When searching for clues to reach a diagnosis, neurologists often empathise with the detective who is trying to solve a case, write Peter Kempster and Andrew Lees in JNNP sister journal Practical Neurology bit.ly/1dqReQq.In this podcast, journal editor Phil Smith and Andrew Lees, director of the Queen Square Brain Bank in London, discuss how neurologists draw upon detective skills. They also talk about neurologists who have turned these skills to crime fiction writing, and the use of narrative i

Jan 09,2014 19:44

114. Radiation for brain metastases, and the genetics of ischaemic stroke

This month, whole brain radiation vs radiosurgery for cerebral metastases. Does the former cause significantly more cognitive defects, and are any blanket, mopping up effects worth it? Clark Chen, vice chairman of neurosurgery, University of California San Diego, talks us through his review.And a clinical guide to the genetics of ischaemic stroke, from Pankaj Sharma, Imperial College Cerebrovascular Research Unit.Read the full papers:Review: Genetics of ischaemic stroke bit.ly/1aptzNlNeurocogni

Nov 26,2013 27:14

115. Education special: Headache

Callum Duncan, neurologist at Aberdeen Royal Infirmary, convenes a round table of experts to discuss advances in headache, particularly the pathophysiological understanding of cluster headache, managing cluster headache and migraine, and new onset chronic daily headache.Taking part are:Phillip Holland, postdoctoral researcher, Centre for Cognitive and Neural Systems, University of EdinburghManjit Matharu, clinical lead of the Headache Group at The National Hospital for Neurology and Neurosurgery

Nov 26,2013 19:44

116. Aggressive MS, and disappointment following deep brain stimulation for Parkinson’s

This month, getting a handle on aggressive multiple sclerosis. Suresh Menon and Helen Tremlett, both from the Department of Medicine, University of British Columbia, talk us through their recent step towards a definition of the disease.And Parkinson's patients who are disappointed after deep brain stimulation, despite gaining motor benefits and quality of life improvements. Catherine Lewis and Franziska Maier, both from the Department of Neurology, University of Cologne, explain how to predict w

Oct 25,2013 21:05

117. Vitamin D, sunlight, and MS

October's JNNP takes another step towards demystifying the relationship between sunlight, vitamin D, and MS, featuring a paper which reveals sun exposure may have direct effects on neurodegeneration independently of the vitamin.Murali Ramanathan, co-author of the study and professor of pharmaceutical sciences and neurology at the State University of New York at Buffalo, talks us through the research.Read the full paper, for free, here: bit.ly/171jo6N

Oct 15,2013 10:40

118. Education special: Neurogenetics update

Ralph Gregory, secretary for the Association of British Neurologists and consultant neurologist in Dorset, gets an update on neurogenetics research and implications for practice from Nick Wood, professor of clinical neurogenetics, Institute of Neurology.This podcast is one of a series produced in collaboration with the Association of British Neurologists, of which there will be more to come over the next few months. You can find all the podcasts in the series here: soundcloud.com/tags/abn%202013

Oct 15,2013 09:39

119. Diagnosing and treating neuromyelitis optica

Neuromyelitis optica (NMO) is an autoimmune inflammatory disorder with predilection for the optic nerves and spinal cord. Many recent advances, in particular, the discovery of NMO-IgG, an NMO-specific autoantibody, have furthered our understanding of the condition. Anu Jacob, consultant neurologist, The Walton Centre for Neurology and Neurosurgery, Liverpool, summarises what clinicians need to know in terms of diagnosing and treating NMO and its spectrum disorders.Read the full review, for free,

Aug 19,2013 21:29

120. Diagnosing the dementias

This month, we get an update on the latest in clinically diagnosing the dementias, with a roundtable of experts convened by the Association of British Neurologists. Taking part are John Greene, Southern General Hospital, Glasgow, Chris Butler, Department of Clinical Neurology, University of Oxford, Nick Fox, Dementia Research Centre, UCL Institute of Neurology, and Huw Morris, Cardiff University School of Medicine.And using theory of mind deficits as an early marker of frontotemproal dementia. M

Jul 23,2013 27:58

121. Anti-GQ1b antibody syndrome, and ALS and language deficits

We know that ALS is associated with executive dysfunction, but what about language deficits? Steven Wing, specialist neurology registrar at Addenbrooke’s Hospital, Cambridge, talks to Laura Goldstein, professor of Clinical Neuropsychology at the Institute of Psychiatry, about her recent paper investigating this.And anti-GQ1b antibody syndrome, or Bickerstaff brainstem encephalitis and Fisher syndrome. Editor Matthew Kiernan talks to Nobuhiro Yuki, Department of Medicine, National University of S

Jul 05,2013 27:39

122. Striatal cell transplants for Huntington’s disease: where are we now?

In Huntington’s disease the striatum takes a big hit early. This has prompted trials of foetal stratal transplantation, in the hope that this may provide some relief to patients.Stevan Wing, specialist neurology registrar at Addenbrooke’s Hospital, and researcher, University of Cambridge, speaks to Professor Roger Barker, John van Geest Centre for Brain Repair, University of Cambridge, about his experience of leading a transplant trial with the NEST-UK consortium.See also:The long-term safety an

Jul 05,2013 20:28

123. Education special: MS update

Ralph Gregory, secretary for the Association of British Neurologists and consultant neurologist in Dorset, gets an update on multiple sclerosis research and implications for practice from Neil Robertson, professor of neurology, Cardiff University.They discuss new therapeutics BG-12 and alemtuzumab, the understanding of treatment risks, prognosis, prevalence and incidence, and MS and pregnancy.This podcast is one of a series produced in collaboration with the Association of British Neurologists,

Jun 11,2013 14:40

124. Education special: Peripheral nerve disease update

Ralph Gregory, secretary for the Association of British Neurologists and consultant neurologist in Dorset, gets an update on peripheral nerve disease research and practice from James Overell, consultant neurologist, Institute of Neurological Sciences, Glasgow.They discuss treatment for CIDP, differences in neuropathy prevention and management in type 1 and type 2 diabetes, chronic inflammatory neuropathies, and hereditary motor sensory neuropathies.This podcast is one of a series produced in col

Jun 11,2013 20:02

125. Stem cells in neurology, and enlarged perivascular spaces and intracerebral haemorrhage

Where are we with stem cell treatments for stroke and Parkinson’s disease? At the Association of British Neurologists’ recent annual meeting in Glasgow, Neil Scolding, director of the Bristol Institute of Clinical Neurosciences, spoke to Keith Muir, Institute of Neuroscience and Psychology, Univeristy of Glasgow, and Roger Barker, John van Geest Centre for Brain Repair, University of Cambridge, about current research, and the expensive, unproven treatments already on the market.And using enlarge

Jun 11,2013 33:57

126. Parkinson’s disease subtypes: lost in translation?

This month Connie Marras, assistant professor of neurology, University of Toronto, talks us through her review of Parkinson’s disease subtypes.What definitions do we have so far, what could they tell us about the condition, and how can we get them incorporated into research more?See also:Parkinson’s disease subtypes: lost in translation? http://bit.ly/12mKxYL

May 01,2013 12:51

127. The latest on stroke

In this special edition of the podcast, JNNP associate editor Nick Ward looks into some of the latest research into stroke.Tracking cognitive function in those recovering from stroke in routine. Owen White, associate professor, Department of Neurology, Royal Melbourne Hospital, describes how assessing ocular motor deficits is a sensitive way of doing this. Furthermore, he describes the computerised programme he’s come up with to treat these, and why he believes doing so will lead to improvement

May 01,2013 33:49

128. Dopamine agonist withdrawal syndrome

The problem of those with Parkinson’s disease becoming addicted to dopamine replacement therapy is well know, but it’s also now emerging that some patients have trouble coming of dopamine agonists.Margarita Pondal, from the Movement Disorders Centre, University of Toronto, talks us through her study looking at the prevalence of the syndrome, and the patients who are most likely to be affected.See also:Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic http:/

May 01,2013 10:44

129. BNPA 2013: The impact of epilepsy on cognitive function

Cognitive impairment in those with epilepsy is common. Adam Zeman, professor of cognitive and behavioural neurology, University of Exeter, ask Christoph Helmstaedter, associate professor for clinical neuropsychology, the University Clinic of Epileptology in Bonn, about the association, including the effects antiepileptic drugs can have on cognition.Further resources:Helmstaedter C, Witt JA. Clinical neuropsychology in epilepsy: theoretical and practical issues. Handb Clin Neurol. 2012;107:437-59

Feb 18,2013 11:13

130. BNPA 2013: Psychedelic drugs, magical thinking and psychosis

Robin Carhart-Harris, post-doctoral researcher, Division of Brain Sciences, Imperial College London, explains his hypothesis on the shared neurobiology of psychosis, psychedelic states and spontaneous spiritual experiences to Peter Halligan, professor in the School of Psychology, Cardiff University.This podcast was recorded at the British NeuroPsychiatry Association’s 2013 AGM. For more information on the association and next year’s meeting, see bnpa.org.uk.

Feb 18,2013 06:39

131. BNPA 2013: Decoding consciousness

What relevance does consciousness have for our understanding of mental conditions? Geraint Rees, deputy head of the UCL Faculty of Brain Sciences, tells Peter Halligan, professor in the School of Psychology, Cardiff University, about his work in the area.This podcast was recorded at the British NeuroPsychiatry Association’s 2013 AGM. For more information on the association and next year’s meeting, see bnpa.org.uk.

Feb 18,2013 03:48

132. BNPA 2013: Epilepsy, depression and anxiety disorders

There is a complex relationship between epilepsy, depression, and anxiety disorders. Adam Zeman, professor of cognitive and behavioural neurology, University of Exeter, discusses the associations and what they mean for practice with Andres Kanner, director of the Comprehensive Epilepsy Center, University of Miami.This podcast was recorded at the British NeuroPsychiatry Association’s 2013 AGM. For more information on the association and next year’s meeting, see bnpa.org.uk.

Feb 18,2013 11:55

133. BNPA 2013: Brain networks in human epilepsy

How epileptic seizures start is unclear. Mark Richardson, professor of epilepsy, Institute of Psychiatry, is working on elucidating this question using computational models. He talks Markus Reuber, professor of clinical neurology, University of Sheffield, through his research.This podcast was recorded at the British NeuroPsychiatry Association’s 2013 AGM. For more information on the association and next year’s meeting, see bnpa.org.uk.For more on Professor Richardson’s work on brain models in ep

Feb 18,2013 07:15

134. BNPA 2013: Cellular mechanisms of epilepsy

Markus Reuber, professor of clinical neurology, University of Sheffield, discusses the different cellular mechanisms which allow seizures in epilepsy to happen, and how this understanding could lead to disease modification with John Jefferys, professor of neuroscience, University of Birmingham.This podcast was recorded at the British NeuroPsychiatry Association’s 2013 AGM. For more information on the association and next year’s meeting, see bnpa.org.uk.

Feb 18,2013 07:46

135. BNPA 2013: Autoimmunity and neuropsychiatry

Tim Nicholson, academic clinical lecturer, Institute of Psychiatry, gives Hugh Rickards, consultant in neuropsychiatry, University of Birmingham, an update on autoimmune mechanisms and encephalitis. Dr Nicholson covers where we are with understanding and treating paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS), and also NMDA-receptor encephalitis.This podcast was recorded at the British NeuroPsychiatry Association’s 2013 AGM. For more informatio

Feb 18,2013 10:56

136. BNPA 2013: Deep brain stimulation for mental illness

Eileen Joyce, professor in neuropsychiatry at the Institute of Neurology, gives Hugh Rickards, consultant in neuropsychiatry, University of Birmingham, an update on the use of deep brain stimulation to treat mental disorders, particularly OCD.This podcast was recorded at the British NeuroPsychiatry Association’s 2013 AGM. For more information on the association and next year’s meeting, see bnpa.org.uk.

Feb 18,2013 08:50

137. BNPA 2013: The neural correlates of Freudian “repression” in conversion disorder

Selma Aybek, clinician researcher, Service of Neurology, University of Lausanne, has been examining the process which allows psychological stressors to become physical symptoms in conversion disorder. Chris Butler, academic clinical lecturer in neurology, University of Oxford, asks her what she’s found.This podcast was recorded at the British NeuroPsychiatry Association’s 2013 AGM. For more information on the association and next year’s meeting, see bnpa.org.uk.

Feb 18,2013 07:05

138. BNPA 2013: Effects of early childhood posterior fossa tumours on IQ

Cliodhna Carroll, along with colleagues at the University of Cambridge, has shown that children who’ve had a posterior fossa tumour have a lower IQ than matched controls. She talks Chris Butler, academic clinical lecturer in neurology, University of Oxford, through the research and its implications.This podcast was recorded at the British NeuroPsychiatry Association’s 2013 AGM. For more information on the association and next year’s meeting, see bnpa.org.uk.

Feb 18,2013 07:35

139. BNPA 2013: Epilepsy and affective disorders, the role of the subgenual prefrontal cortex

Chris Butler, academic clinical lecturer in neurology, University of Oxford, talks to Rebecca Cleary, research assistant, Wellcome Trust Centre for Neuro-imaging, UCL, about her research investigating whether the neural substrate in those with depression or anxiety is the same as in those with one of these disorders and also temporal lobe epilepsy.This podcast was recorded at the British NeuroPsychiatry Association’s 2013 AGM. For more information on the association and next year’s meeting, see

Feb 18,2013 07:34

140. BNPA 2013: Stress and war, and the limits of neuropsychiatry

Neil Greenberg, academic psychiatrist, Kings College London, who’s served in the armed forces for more than 20 years, argued in his JNNP-sponsored keynote at BNPA that we understand many of the issues in military mental health, and that the neuropsychiatric element is relatively small. Alan Carson, JNNP associate editor, talks to him about the impact of being in the military on mental health beyond PTSD.This podcast was recorded at the British NeuroPsychiatry Association’s 2013 AGM. For more inf

Feb 18,2013 09:40

141. BNPA 2013: Childhood stress and risk for later mental disorder

David Skuse, professor in the Behavioural Sciences Unit, Institute of Child Health, talks to Jeremy Hall, professor of psychiatry and neuroscience at the University of Cardiff, about his work investigating the link between childhood stress and borderline personality disorder.This podcast was recorded at the British NeuroPsychiatry Association’s 2013 AGM. For more information on the association and next year’s meeting, see bnpa.org.uk.

Feb 18,2013 10:19

142. BNPA 2013: Inflammation and mental illness

Alan Carson, JNNP associate editor, talks to Neil Harrison, consultant neuropsychiatrist and head of psychoneuroimmunology, Brighton and Sussex Medical School, about what we currently know about inflammation in mental disorders. Dr Harrison also discusses the potential of anti-inflammatories to treat depression.This podcast was recorded at the British NeuroPsychiatry Association’s 2013 AGM. For more information on the association and next year’s meeting, see bnpa.org.uk.

Feb 18,2013 07:40

143. BNPA 2013: Posttraumatic stress disorder and the brain

David Skuse, professor in the Behavioural Sciences Unit, Institute of Child Health, asks Chris Brewin, professor of clinical psychology, UCL Faculty of Brain Sciences, about the different forms of PTSD experience, the cognitive processes involved, and how understanding these could inform psychological therapies for the condition.This podcast was recorded at the British NeuroPsychiatry Association’s 2013 AGM. For more information on the association and next year’s meeting, see bnpa.org.uk.

Feb 18,2013 09:41

144. BNPA 2013: Equipped to survive, how comprehensive response to threat enables optimal behaviour

The human response to threat requires comprehensive change in the network properties of the brain, with the whole organ affected. Alan Carson, JNNP associate editor, asks Guillén Fernández, director of the Donders Center for Neuroscience, Radboud University Nijmegen Medical Center, about his work investigating the effects of stressors on brain structure and function.This podcast was recorded at the British NeuroPsychiatry Association’s 2013 AGM. For more information on the association and next y

Feb 18,2013 07:47

145. Discovering Emery-Dreifuss muscular dystrophy, and flavour identification in FTLD

In the last JNNP podcast of 2012, we look at what jelly beans and the Andalucian mountains have done for neurology and psychiatry.Alan Emery, emeritus professor, Green Temple College, University of Oxford, describes studying the family that led him to delineate Emery-Dreifuss muscular dystrophy.And Jason Warren and Rohani Omar, UCL Institute of Neurology, talk about what their study into flavour identification in frontotemporal lobar degeneration reveals.See also:Impact commentary: Unusual type

Feb 15,2013 22:13

146. The future of epilepsy research, assessing hemianopia, measuring sensory nerve action potentials

This month, Mark Richardson, professor of epilepsy, Kings College London, relates his vision for the future of epilepsy research (1.07).Alexander Leff, consultant neurologist, Institute of Cognitive Neuroscience, University College London, discusses his online tool for diagnosing and providing treatment for hemianopia, the visual impairment which can follow stroke or brain injury (14.07).And measuring sensory nerve conduction. Tom Sears, emeritus professor of neurophysiology, King’s College Lond

Feb 15,2013 31:46

147. The Scheltens scale, disability after head injury, and cannabis for multiple sclerosis

This month, we explore the latest research on treating multiple sclerosis with cannabis extract. Editor Matthew Kiernan speaks to John Zajicek, professor of Clinical Neuroscience, Peninsula College of Medicine and Dentistry, UK. (0.54)Received wisdom is that if you are disabled shortly after a head injury, you are not going to see this improve. However Tom McMillan, professor of Clinical Neuropsychology, University of Glasgow, explains how he has shown long term outcomes are actually dynamic. (9

Feb 15,2013 23:04

148. Early days of the Queen Square brain bank; rating dopaminergic replacement therapy response

The Queen Square brain bank was set up by Andrew Lees, and whilst there he co-authored two of JNNP’s most highly cited papers – one on the importance of Lewy bodies in Parkinson’s, and the other on the accuracy of clinical diagnosis of the disease. Now director of the Reta Lila Weston Institute of Neurological studies, University College London, he discusses the changing relationship between pathologists and clinicians, and the progress he’s seen in diagnosis.Assessing response to dopamine repla

Feb 15,2013 31:43

149. Oliver Sacks’s functional paralysis; progressive multifocal leukoencephalopathy

In 1974 Oliver Sacks was hiking through a remote part of Norway when he suffered a nasty injury to one leg. Although he managed to get to help and was successfully operated on, he struggled to relearn to walk and felt alienated from the limb. Jon Stone (consultant neurologist in the Department of Clinical Neurosciences, University of Edinburgh) explains why from Sacks’s writing he thinks this was a case of functional paralysis, and why the account is so valuable.And progressive multifocal leukoe

Feb 15,2013 20:49

150. Recovery after stroke; malingering after concussion

Derick Wade (professor and consultant in neurological rehabilitation at the Oxford Centre for Enablement) and Nick Ward (JNNP associate editor and reader in clinical neurology at UCL) discuss the past, present and future of measuring and predicting recovery after stroke.And poor effort, exaggeration and malingering can be used to explain why individuals post-concussion report persistent symptoms inconsistent with the severity of their injury. However Jonathan Silver (clinical professor of Psychi

Feb 15,2013 27:29

151. The future of glioblastoma therapy

Despite current standard care for glioblastoma being aggressive, mean survival is around 14 months. Clark Chen (director of Clinical Neuro-oncology, Beth Israel Deaconess Medical Center, Boston) argues we need a better understanding of the therapeutic concepts that have evolved over the past three decades to develop treatment, and in a JNNP article this month he lays out seven of these key ideas. Peter Warnke (JNNP associate editor) discusses them with him.See also:Key concepts in glioblastoma t

Feb 15,2013 13:47

152. Neurological symptoms from autoimmune syndromes; movement disorders and OCD; counting strokes

This month, editor Matthew Kiernan discusses new guidelines for recognising central nervous system neuronal surface antibody associated symptoms with Angela Vincent (emeritus professor of neuroimmunology at Oxford University).Danielle Cath (psychiatrist at Altrecht Academic Anxiety Outpatients Clinics, Utrecht University) explains what her review of the relationship between obsessive compulsive disorder and movement disorders reveals.And Charles Warlow (emeritus professor of medical neurology at

Feb 15,2013 34:32

153. Idiopathic intracranial hypertension; discovering the neurological effects of critical illness

This month Beau Bruce (assistant professor of ophthalmology and neurology, Emory University School of Medicine, Atlanta) discusses what we do and don’t know about idiopathic intracranial hypertension, and offers some clinical advice on the syndrome for neurologists.And Charles Bolton (professor in the Department of Medicine, Queen’s University, Ontario, Canada) talks us through his investigations in the 1980s which discovered critical illness could cause neurological problems.See also:Update on

Feb 15,2013 23:19

154. Diagnostic criteria for CBS; tractography in ALS fifty years ago; better tests for bvFTD

In April’s podcast, we put a spotlight on amyotrophic lateral sclerosis and frontotemporal dementia.Maxime Bertoux, a neuropsychologist at Paris-Sorbonne University, discusses the problem of misdiagnosis of the behavioural variant of FTD, and how he’s shown the Social Cognition and Emotional Assessment is a more powerful tool than others in use (20.50).And Martin Turner, consultant neurologist at Oxford University Nuffield Department of Clinical Neuroscience, talks about early tractography work

Feb 15,2013 31:13

155. Surrogate outcomes; CAA and IH; Angela Vincent looks back

This issue we look at short-term outcomes used to assess multiple sclerosis treatments, and their power to predict long-term disability, with Douglas Goodin (professor of clinical neurology, University of California, San Francisco).We return to the association between cerebral amyloid angiopathy and intracerebral haemorrhage, as Neshika Samarasekera (Division of Clinical Neurosciences, University of Edinburgh) talks us through her research examining the link.And Angela Vincent (emeritus professo

Feb 15,2013 26:02

156. Cerebral amyloid angiopathy; lifestyle and mortality after stroke; motor output patterns

This month, cerebral amyloid angiopathy. David Werring (Stroke Research Group, UCL Institute of Neurology and the National Hospital for Neurology and Neurosurgery) discusses the importance of detecting it, especially as he feels it is under-recognised by physicians.What impact does a healthy lifestyle have on mortality following stroke? Amytis Towfighi (Division of Stroke and Critical Care, Department of Neurology, University of Southern California) tells us what her research found.And lastly, a

Feb 15,2013 22:33

157. The early days of chronic fatigue syndrome research; Clues to functional weakness mechanism

In this first podcast of 2012 editor Matthew Kiernan talks about JNNP’s new impact commentaries - a series which will explore influential papers from the journal. A paper by Simon Wessely (King’s College London) comparing postviral fatigue with that of neuromuscular and affective disorders is the first covered, and he and Matthew discuss this seminal research.Also, Jon Stone (University of Edinburgh) explains what his investigation into the nature of functional weakness onset indicates about the

Feb 15,2013 29:38

158. Diagnosing delirium

This month we discuss the issue of diagnosing delirium in older hospital patients. Despite being linked to a range of poor outcomes, the syndrome is often missed and evidence on its measurement is sparse.Professor Alasdair MacLullich tells us how a device he’s designed with colleagues at the University of Edinburgh, which tests for delirium’s attentional deficits, can benefit clinicians and researchers.See also:Detecting deficits of sustained visual attention in delirium http://tinyurl.com/aswwb

Feb 15,2013 12:55

159. Diagnosing conversion disorder; exercise to prevent falls in Parkinson’s patients

In this edition Richard Kanaan (Institute of Psychiatry, King’s College London) talks about his work on conversion disorder, and gives his advice for neurologists and psychiatrists on making this tricky diagnosis.And Vicki Goodwin (Peninsula College of Medicine and Dentistry, University of Exeter) discusses her trial on whether an exercise intervention could prevent falls in those with Parkinson’s disease.See also:Conversion disorder: a problematic diagnosis http://tinyurl.com/agrtdxsAn exercise

Feb 15,2013 21:28

160. The natural history of Parkinson’s; the latest on MS and latitude

Current treatments for Parkinson’s ameliorate the core, motor symptoms. However as we look for therapies to modify the underlying course of the disease there’s a need to better understand its development. Jonathan Evans, from the Cambridge Centre for Brain Repair, University of Cambridge, UK, explains what his work has revealed, and how it can progress treatment.And the latest evidence in the debate on whether multiple sclerosis prevalence increases with latitude. Steve Simpson Jnr, Menzies Rese

Jan 29,2013 19:06

161. Athleticism and ALS; understanding peripherally induced movement disorders

Movement disorders following head trauma are well recognised, but we know much less about those occuring after a peripheral injury. Diana van Rooijen, Leiden Medical Center, the Netherlands, tells us what her review on this group of conditions reveals (0.58).Clinicians are used to seeing ALS patients who are or have been athletic. So is there a link, and if so, could exercise have a direct effect on the condition? Dr Martin Turner, John Radcliffe University Hospital, Oxford, talks us through his

Jan 29,2013 19:05

162. Thrombolysis for elderly stroke patients; disability with organically-unexplained symptoms

Intravenous thrombolysis is the only curative treatment for acute ischaemic stroke, but is only licensed for patients up to 80 years old. Dr Paul Guyler, Southend Hospital NHS Trust, UK, discusses the evidence for outcomes in those over this limit, and whether or not doctors should treat off-licence.Also in this July edition, Dr Alan Carson, Western General Hospital, Edinburgh, UK, on his research into disability, distress and employment in neurology outpatients who’s symptoms can’t be explaine

Jan 29,2013 20:27

163. Finger length ratio and ALS; psychotherapy for dizziness

Dizziness can significantly complicate peoples’ lives, especially if it does not have a satisfactory medical explanation. We talk to Dr Gabriele Schmid of the Department of Psychosomatic Medicine and Psychotherapy, Technical University of Munich, Germany, about how psychotherapy might be beneficial for these patients.Also in this month’s podcast, Professor Ammar Al-Chalabi of King’s College London discusses the link between prenatal testosterone levels and ALS.See also:Psychotherapy in dizziness

Jan 29,2013 10:58

164. Frontotemporal dementia reviewed; temporal orientation and dementia

Recent clinical, neuropsychological, imaging, genetic and pathological developments have changed our understanding of frontotemporal dementia, its classification and criteria. Dr Jonathan Rohrer, Dementia Research Centre, UCL Institute of Neurology, London, talks about these advances and future research directions.Also in this edition, Dr Shaun O’Keeffe, Merlin Park University Hospital, Dublin, explains how simple questions about time are, and should be, used to assess dementia and delirium.See

Jan 29,2013 18:33

165. Dementia and word knowledge; DBS for Parkinson’s

This month Robert Wilson, Rush University Medical Center, Chicago, USA, on how dementia affects our knowledge of words, and the neuropathology which underlies this.Also, the use of deep brain stimulation to treat Parkinson’s disease. Tom Foltynie describes the image guided, rather than microelectrode guided, technique used at the National Hospital of Neurology and Neurosurgery, London, UK, and the success they’ve had.See also:MRI-guided STN DBS in Parkinson’s disease without microelectrode recor

Jan 29,2013 17:55

166. Genes, vitamin D and MS; hysteria and hypnosis

It’s been known for years that the prevalence of MS increases the further you go from the equator, but not why. Roisin Lonergan, from St Vincent’s University Hospital, Dublin, Ireland, describes her investigations into a genetic factor and vitamin D levels, and if they can help explain this.Also Quinton Deeley, from the Institute of Psychiatry at London’s King’s College, UK, talks about hysteria and hypnosis, and why they could stem from similar brain processes.See alsoMultiple sclerosis prevale

Jan 29,2013 17:12

167. Eye movements in motor neurone disease; work and multiple sclerosis

This month Harriet Vickers (BMJ’s multimedia intern), talks to Solveig Glad about how long patients with benign multiple sclerosis stay in work, and what could help them hold down jobs.Also Colette Donaghy explains how examining eye movements in amyotrophic lateral sclerosis could help with diagnosis, and tell us more about the pathophysiology of the disease.See also:How long can you keep working with benign multiple sclerosis? http://tinyurl.com/bxjogdoEye movements in amyotrophic lateral scler

Jan 29,2013 15:54

168. October 2010

In this month’s podcast Dr Amal Al Sayegh tells us about psychological therapies for treatment of post-concussion syndrome, and Dr Serena Hung describes patient’s perceptions of dyskinesia in Parkinson’s disease.See also:Psychological approaches to treatment of postconcussion syndrome: a systematic review http://tinyurl.com/bgcfkclPatient perception of dyskinesia in Parkinson’s disease http://tinyurl.com/bcqeav3

Jan 29,2013 15:44

169. Predicting adjustment to an ALS diagnosis

Tamara Matuz discusses her research looking for predictors for how well patients adjust to a diagnosis of ALS in southern Germany.

Jan 29,2013 15:44

170. Microbleeds and abuse in dementia

In this month’s podcast David Werring from University College London talks about his research into the link between brain microbleeds and intercerebral haemmorhage. Claudia Cooper explains her research looking at abusive behaviour by dementia patients towards their carers.See also:Abusive behaviour experienced by family carers from people with dementia http://tinyurl.com/bjw6n2eBrain microbleeds as a potential risk factor for antiplatelet-related intracerebral haemorrhage http://tinyurl.com/bzso

Jan 29,2013 14:07

171. Migrane co-morbidities

In this month’s podcast Dawn Buse from the Montefiore Headache Center, New York, talks about her research into co-morbidities in chronic migrane sufferers.See also: Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers http://tinyurl.com/b3x44vm

Jan 29,2013 14:07

172. The SCAN rule

Matthew Kiernan (editor of JNNP) interviews Caroline Lovelock about her paper: The SCAN rule: a clinical rule to reduce CT misdiagnosis of intracerebral haemorrhage in minor stroke. This paper was the editor’s choice in the March edition of JNNP.

Jan 29,2013 11:00

173. Epilepsy and driving; Self awareness in dementia

In this second podcast Professor Matthew Kiernan talks to Dr Rhys Thomas about the law regarding sleep-related epilepsy and driving - this month’s editor’s choice paper.Also Duncan Jarvies talks to Dr Howard Rosen about his research into self awareness in dementia patients - this month’s patient’s choice paper.For more information please see:Awake seizures after pure sleep-related epilepsy: a systematic review and implications for driving law http://tinyurl.com/a6jfzcrStandardised measurement of

Jan 29,2013 18:18

174. Pregnancy and MS

We are delighted to offer you the inaugural podcast from JNNP. Recorded at BMA House London, our broadcast begins with a future vision for the journal from incoming Editor, Professor Matthew Kiernan based in Sydney. There then follows a discussion with Dr Marie D’hooghe from the National Multiple Sclerosis Centre in Belgium. Marie and Matthew discuss the long-term effects of childbirth in patients diagnosed with multiple sclerosis and uncover some interesting insights. They chat about: How wo

Jan 29,2013 13:53

All Episodes (174) From new to old From new to old From old to new

All Episodes (174)

From new to old

From new to old From old to new